As per the agreement between Sandoz and Slayback, terms of which remain confidential, Sandoz will continue to pay Slayback a share of the profits generated from the sale of Acyclovir Ointment in the USA.
"Slayback's core focus is the development of complex generics primarily in parenteral and other non-solid pharmaceutical products by connecting the dots across various technologies, science, regulatory and intellectual property traditions. The successful development and approval of a complex generic formulation of Acyclovir Ointment meeting FDA's standards is a testimony to this effort," said Ajay K Singh, Chief Executive Officer of Slayback Pharma LLC.
About Slayback Pharma LLC
Slayback Pharma LLC is a specialty pharmaceutical company focused on developing, manufacturing and sourcing of complex generic pharmaceutical products, with a specific emphasis on complex injectables and other non-solid oral products. Slayback has created a unique portfolio of complex generic by smart product selection and execution and connecting various dots through a network of contract R&D laboratories and manufacturing organizations, comprising smart and rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/slayback-pharma-announces-the-final-approval-and-launch-of-generic-zovirax-acyclovir-ointment-5-300383519.html
SOURCE Slayback Pharma LLC